All Press Releases

Home»All Press Releases
26 05, 2020

Eiger to Present at Jefferies Virtual Healthcare Conference 2020

2020-05-26T21:20:28+00:00

Eiger to Present at Jefferies Virtual Healthcare Conference 2020 PALO ALTO, Calif. – May 26, 2020 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies Virtual Healthcare Conference on June 4, [...]

Eiger to Present at Jefferies Virtual Healthcare Conference 20202020-05-26T21:20:28+00:00
19 05, 2020

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies

2020-05-19T21:14:10+00:00

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies PALO ALTO, Calif. May 19, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug [...]

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies2020-05-19T21:14:10+00:00
7 05, 2020

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

2020-05-07T20:42:20+00:00

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update PALO ALTO, Calif. May 7, 2020 — Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update. “We achieved key milestones [...]

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update2020-05-07T20:42:20+00:00
30 04, 2020

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda

2020-04-30T13:57:03+00:00

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda Six International, Investigator Sponsored Studies Initiating and Enrolling PALO ALTO, Calif. April 30, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients have been dosed in [...]

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda2020-04-30T13:57:03+00:00
27 04, 2020

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies

2020-04-27T13:57:56+00:00

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies Accelerated Assessment of MAA Previously Granted by EMA in March PALO ALTO, Calif. April 27, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that [...]

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies2020-04-27T13:57:56+00:00
3 04, 2020

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic

2020-04-03T11:04:09+00:00

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating   PALO ALTO, Calif. April 1, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare [...]

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic2020-04-03T11:04:09+00:00
23 03, 2020

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

2020-03-23T17:54:46+00:00

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies Progeria MAA Submitted to EMA and Granted Accelerated Assessment PALO ALTO,  Calif. March 23, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, [...]

Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies2020-03-23T17:54:46+00:00
7 01, 2020

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

2020-01-07T14:48:46+00:00

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer Launch Preparation Underway for Lonafarnib in Progeria Market Development Activities Advancing for HDV Program PALO ALTO, Calif., January 7, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies [...]

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer2020-01-07T14:48:46+00:00
15 11, 2019

Eiger to Present at Jefferies 2019 London Healthcare Conference

2019-11-15T17:27:31+00:00

Eiger to Present at Jefferies 2019 London Healthcare Conference PALO ALTO, Calif. – November 15, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies 2019 London Healthcare Conference on November [...]

Eiger to Present at Jefferies 2019 London Healthcare Conference2019-11-15T17:27:31+00:00
12 11, 2019

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results

2019-11-12T21:55:21+00:00

Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 Median Decline of HDV RNA: -3.4 Log at Week 24 95% of Patients Achieve > [...]

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results2019-11-12T21:55:21+00:00